ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xiang Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-4543-2767; OpenAlex author ID A5026354104. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

Neoadjuvant Therapy for Resettable Pancreatic Adenocarcinoma: It's Time to Define High-Risk Factors. Co-author DOI 10.1002/jso.28082 ↗
Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]Ga-FAPI-04. Co-author DOI 10.1007/s00259-022-06010-5 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shunqi Xie · 1 shared paper, 2025 · strength 0.54
- Paper Neoadjuvant Therapy for Resettable Pancreatic Adenocarcinoma: It's Time to Define High-Risk Factors. DOI 10.1002/jso.28082 ↗
Jianjun Liu · 1 shared paper, 2023 · strength 0.18
- Paper Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]… DOI 10.1007/s00259-022-06010-5 ↗
Ruohua Chen · 1 shared paper, 2023 · strength 0.18
- Paper Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]… DOI 10.1007/s00259-022-06010-5 ↗
Haitao Zhao · 1 shared paper, 2023 · strength 0.18
- Paper Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]… DOI 10.1007/s00259-022-06010-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.